Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by AntibeTribeon Feb 29, 2020 10:15am

130 Views

Post# 30750769

RE:RE:RE:Don’t Skin Me Alive MugsMods

*Cheers* to this.

mstrmnd wrote:
2 functions:
1) The obvious - hard to convince people of what lays ahead when people live on trends and curves (and likely on the financial edge) when Covid-19's impact is universal. If the markets bounce back next week, this is as close to a sure investment as you get in the next 8 weeks relative to alternatives. This Covid-19 collapse window overlaps with the most exciting time in Antibe, so money will be much safer here than elsewhere. There should be steady climbs in the next 2, 4, 6, 8 weeks including any big pharma plans or annoucements.
2) When you fill to 100% this slow, it's no surprise to anyone on the inside that the final entrant is in (about time!). In fact, slow recruitment with this many sites is a VERY strong indicator of the quality of the trial and increases the chances of success even more (totally less risk than aggressive sloppy recruitment). The human psyche and its PTSD after losing money triggers a very strong fear aversion (everyone is on a scale of 0-10) - so today was a great day to buy, where short-term risk is now totally gone, but because eyes were all over the place purely to monitor and stop bleeding (noise), the market didn't pay attention to ATE.V. Great value for the 2 million shares today.

Very simple:

The TSX Ventures completely devalues ATE.V. Totally undervalued. ATE.V is buried in the trees where helicopters are not looking

Ridiculous updside though. In the US, you can only imagine where ATE should be trading today. The Phase 2a and 2b trials are magnificently designed that its in fact Phase 3 quality. The company's strategy is very clear:

1) Set up big pharma talks well in advance to lay the foundation for an acquisition - CHECK
2) Complete Phase 3 quality RCTs in Phase 2 to de-risk Phase 3 for Big Pharma - CHECK

(the kicker - if its 2 trials with primary outcome this strong with p < 0.001="" -="" it's="" remarkably="" clear="" this="" is="" a="">medical blockbluster that could change the way doctor's prescribe globaly, and with these strong of results, Big Pharma could gobble them up unexpectedly).

Pre-arranged buyout after Phase 2B vs. Pharma Bidding War set up

If someone doesn't buy this company in the next 12 months - I will be shocked.